Ipamorelin

Posted on October 26, 2013 by Maxim Peptide

Ipamorelin is a secretagogue peptide. This means that it can play a part in the regulation and control of body
weight as well as energy homeostasis in animal test subjects. It is comparable to the peptide GHRP-6 with one of
the primary differences being that Ipamorelin is a penta-peptide and not a he!a-peptide meaning that the peptide
consists of fi"e sides instead of si!. It is considered to be an agonist# that is it has the ability to bind to certain
receptors of a cell and trigger a cellular response. The peptide is a"ailable for purchase of the e!pressed e!clusi"e
use of scientific study and research on animal test subjects. It is administered to animal test subjects through
subcutaneous injection as part of ongoing scientific study conducted to research its properties and operational
mechanisms.
Ipamorelin$s %echanics
&ccording to scientific research conducted on animal test subjects Iparmorelin$s main function is to stimulate the
pituitary gland. This is the pea-si'ed gland found at the brain$s base and it is responsible for regulating an
organism$s endocrine-based functionality. The "arious functions lin(ed to the gland include)
Regulation of thyroid gland function
Pain relief
Regulation of temperature
Regulation of blood pressure
Regulation of bodily growth
Part of Ipamorelin$s mechanics is that it stimulates the
production of growth-related secretions from the pituitary
gland of animal test subjects. &t the same time Ipamorelin
has been determined through scientific research conducted
on animal test subjects to bloc( the production of
somatostatin# a peptide that is primarily responsible for
bloc(ing the release of growth secretions. &dditionally the
peptide has been shown to ele"ate the production of IG*-
+. This secretion also (nown as Insulin-,i(e Growth
*actor + or somatomedin - is comparable to the molecular
build of insulin which is e!pressed in animal test subjects
as an endocrine secretion which through scientific
research has determined to be the main anabolic
mechanism of action for secretions related to growth. This segment of the peptide$s functionality ma(es it a(in to
the operational tendencies of GHRP-6. Howe"er unli(e GHRP-6 Ipamorelin functions to bind to major control
points of gastric appetite and growth motility. In other words scientific research on animal test subjects ha"e
determined that the peptide does not e"o(e an ele"ation in hunger le"els which has been determined to be an
effect of GHRP-6.
&dditionally scientific studies on animal test subjects show that Ipamorelin does not significantly ele"ate the
production le"els of cortisol# the hormone found in animal test subjects that raise blood sugar through the
methodology of gluconeogenesis. It also does not significantly ele"ate the production le"els of prolactin# the
hormone that plays a significant role in regulating the immune system of animal test subjects primarily as it relates
to lactation.
Theoretical .enefits of Ipamorelin
/cientific research that has been conducted on animal test subjects has determined a host of different theoretical
benefits which ha"e been lin(ed to Ipamorelin. These theoretical benefits include)
Reju"enation of joints
/trengthening of connecti"e tissue
/trengthening of joints
Increased fat loss
Impro"ed s(in tone
/trengthening of bone mass
These (inds of positi"e benefits ha"e led some scientific studies to determine that the peptide could be beneficial in
conjunction with the slowing down of the aging process.
Potentially Negative Side Effects of Ipamorelin
&ccording to scientific research that has been conducted on animal test subjects the potentially negati"e side
effects of Ipamorelin has been determined to be minimal. These negati"e side effects ha"e chiefly been (nown to
consist of headaches and head rushes 0that is a feeling of light-headedness1. The research that has been
conducted on animal test subjects has determined that these side effects are generally mild in their nature.
*urthermore the list of negati"e side effects has been determined to be much shorter than the list of negati"e side
effects that are typically tied to the peptide GHRP-6.
For Clinical Research Only
&lthough scientific study conducted on animal test subjects ha"e determined an outline relating to Ipamorelin$s
functionality and operational mechanisms it should be noted that wor( with the peptide is still currently in the
research stage. &ny positi"e benefits or negati"e side effects that ha"e been documented through scientific
research on animal test subjects is still a product of ongoing and not conclusi"e research. &s such any matters of
purchase relating to this peptide must e!clusi"ely be contained to scientific research and any study should be
contained to the confines of a strictly controlled en"ironment such as a laboratory or a medical research facility.